Heart and Vascular Institute at the University of Pittsburgh Medical Center, Pittsburgh, PA, United States of America.
Heart and Vascular Institute at the University of Pittsburgh Medical Center, Pittsburgh, PA, United States of America.
Prog Cardiovasc Dis. 2021 May-Jun;66:46-52. doi: 10.1016/j.pcad.2021.04.003. Epub 2021 Apr 16.
Cardiac resynchronization therapy (CRT) is an established treatment for patients with heart failure (HF), myocardial dysfunction and prolonged ventricular depolarization on surface electrocardiogram. CRT can be delivered by a pacemaker (CRT-P) or a combined pacemaker-defibrillator (CRT-D). Although these two types of devices are very different in size, function, and cost, current published guidelines do not distinguish between them, leaving the choice of which device to implant to the treating physician and the informed patient. In this paper, we review the published CRT clinical trial literature with focus on the outcomes of HF patients treated with CRT-P versus CRT-D. We also attempt to provide guidance as to the appropriate choice of CRT device type, in the absence of randomized prospective trials geared to answer this specific question.
心脏再同步治疗(CRT)是心力衰竭(HF)、心肌功能障碍和体表心电图上心室去极化延长患者的既定治疗方法。CRT 可通过起搏器(CRT-P)或心脏再同步治疗除颤器(CRT-D)提供。尽管这两种类型的设备在尺寸、功能和成本上有很大的不同,但目前发布的指南并没有对它们进行区分,而是将选择植入哪种设备的权利留给治疗医生和知情患者。在本文中,我们回顾了已发表的 CRT 临床试验文献,重点关注接受 CRT-P 与 CRT-D 治疗的 HF 患者的结局。在缺乏针对这一特定问题的随机前瞻性试验的情况下,我们还试图就 CRT 设备类型的适当选择提供指导。